Bausch Health Companies Stock Today
| BHC Stock | USD 9.42 0.08 0.84% |
Performance24 of 100
| Odds Of DistressLess than 28
|
Bausch Health is trading at 9.42 as of the 8th of November 2024, a 0.84 percent decrease since the beginning of the trading day. The stock's open price was 9.5. Bausch Health has about a 28 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat solid performance during the last 90 days. Note, on February 25, 2020, Representative Susie Lee of US Congress acquired under $15k worth of Bausch Health Companies's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 29th of March 1994 | Category Healthcare | Classification Health Care |
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company has 367.8 M outstanding shares of which 12.03 M shares are currently shorted by investors with about 5.17 days to cover. More on Bausch Health Companies
Moving together with Bausch Stock
| 0.74 | DMAC | DiaMedica Therapeutics Earnings Call This Week | PairCorr |
Moving against Bausch Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Bausch Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | William Humphries | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Bien Hoa Concrete JSC | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ARCA Pharmaceutical, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal Testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBausch Health can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Bausch Health's financial leverage. It provides some insight into what part of Bausch Health's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bausch Health Companies (BHC) is traded on New York Stock Exchange in USA. It is located in 2150 St. ElzEar Boulevard West, Laval, QC, Canada, H7L 4A8 and employs 20,270 people. Bausch Health is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 3.53 B. Bausch Health Companies runs under Pharmaceuticals sector within Health Care industry. The entity has 367.8 M outstanding shares of which 12.03 M shares are currently shorted by investors with about 5.17 days to cover.
Bausch Health Companies has about 564 M in cash with 1.03 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.34.
Check Bausch Health Probability Of Bankruptcy
Ownership AllocationBausch Health holds a total of 367.8 Million outstanding shares. The majority of Bausch Health Companies outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Bausch Health Companies to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Bausch Health. Please pay attention to any change in the institutional holdings of Bausch Health Companies as this could imply that something significant has changed or is about to change at the company. Please note that on February 25, 2020, Representative Susie Lee of US Congress acquired under $15k worth of Bausch Health Companies's common stock.
Check Bausch Ownership Details
Bausch Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Mizuho Markets Americas Llc | 2024-06-30 | 7 M | |
| Laurion Capital Management Lp | 2024-06-30 | 6.5 M | |
| Mfn Partners Management, Lp | 2024-06-30 | 6 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 5.4 M | |
| Kohlberg Kravis Roberts & Co Lp | 2024-06-30 | 5.2 M | |
| Arrowstreet Capital Limited Partnership | 2024-06-30 | 4.2 M | |
| Norges Bank | 2024-06-30 | 3.8 M | |
| Bnp Paribas Arbitrage, Sa | 2024-06-30 | 3.3 M | |
| Dimensional Fund Advisors, Inc. | 2024-06-30 | 3.2 M | |
| Icahn Carl C | 2024-06-30 | 34.7 M | |
| Paulson & Company Inc | 2024-06-30 | 26.4 M |
Bausch Health Historical Income Statement
Bausch Stock Against Markets
Bausch Health Corporate Directors
| Sarah Kavanagh | Independent Director | Profile | |
| Richard Schutter | Independent Director | Profile | |
| Amy Wechsler | Independent Director | Profile | |
| Robert Power | Independent Director | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bausch Health Companies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bausch Health. If investors know Bausch will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bausch Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.61) | Earnings Share (0.48) | Revenue Per Share 25.794 | Quarterly Revenue Growth 0.122 | Return On Assets 0.0415 |
The market value of Bausch Health Companies is measured differently than its book value, which is the value of Bausch that is recorded on the company's balance sheet. Investors also form their own opinion of Bausch Health's value that differs from its market value or its book value, called intrinsic value, which is Bausch Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bausch Health's market value can be influenced by many factors that don't directly affect Bausch Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bausch Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bausch Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bausch Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.